Indirizzi operativi per la sorveglianza clinica e ambientale della legionellosi nelle strutture sanitarie e assistenziali della Regione Puglia

La prima epidemia di legionellosi, verificatasi nel luglio del 1976 durante l'American Legion Annua/ Convention a Philadelphia, fece registrare oltre 200 casi con 34 decessi. Solo un anno più tardi, nei laboratori dei Centers far Disease Contrai and Prevention (CDC) dì Atlanta , fu isolato e identificato il microrganismo che, in memoria della prima epidemia, fu chiamato Legionella pneumophila. la sorgente dell' infezione fu individuata nell' impianto di aria condizionata presente nell'hotel. La scoperta suscitò un grande interesse, tale da incoraggiare alcuni studiosi ad effettuare indagini sierologiche retrospettive su campioni di siero provenienti da soggetti affetti da polmonite di origine sconosciuta. Fu possibile in tal modo risalire ad altri episodi epidemici, quali gli eventi accaduti nel 1965 tra i pazienti dell'Ospedale Psichiatrico St. Elisabeth di Washington e nel 1968 tra coloro che lavoravano nel Servizio di Sanità Pubblica di Pontiac (in Michigan). In seguito, si verificarono altre epidemie che hanno contribuito ad approfondire le conoscenze scientifiche non solo sull'etiologia, patogenesi, diagnosi e terapia della legionellosi, ma anche sulle caratteristiche biochimiche, morfologiche e immunologiche dell'agente patogeno, compreso il suo habitat natura le. In Italia, il primo focolaio epidemico risale al 1978 sul Lago di Garda ed interessò 10 soggetti. Da allora le segnalazioni di casi, sia sporadici sia epidemici , sono diventate sempre più frequ enti, anche se è difficile stabilire se questo incremento sia dovuto ad un reale aumento dell' incidenza, al perfezionam ento delle tecniche diagnostiche o ad una maggiore att enzione alla diagnosi e segnalazione dei casi. Nel Sud Italia, la Puglia è tra le regioni con il maggior numero di casi di legionellosi notificati [Notiziar io ISS 2017]. I fattori che rendono diff icile il controllo e la gestione del probl ema sono la disomogeneità nelle procedure di campionamento, le difformità negli intervent i di bonif ica, la scarsa esperienza nella gestione del rischio associato alle diverse concentrazioni di Legionella rilevate nelle reti idriche. L'entità del problema, per la sua complessità, richiede sempre piu un'accurata attenzione a causa delle pesanti conseguenze legali e di immagine che possono coinvolgere sia le strutture sanitarie sia quelle turistico-ricettive, pertanto la Giunta regionale ha approvato nel 2012 il documento Indirizzi per l'Adozione di un Sistema per la sorveglianza e il controllo delle infezioni da Legionella in Puglia, con il quale ha istituito un sistema di rete regionale formato da due livelli organizzativi: uno centrale e l'altro periferico [D.G.R. n. 2261/2012] . Il livello organizzativo centrale è rappresentato da un apposito Nucleo di Riferimento Regionale che definisce percorsi comun i e codificati nell'ambito delle attività di prevenzione e controllo della malattia ed esercita funzioni chiave per la governance del sistema . Il mandato strategico è quello di assumere l'impegno di "regolare" la rete, attraverso un ruolo di att ivazione, sviluppo e manutenzione di procedure codificate tra i componenti della rete stessa. Il livello organizzativo periferico , costituito dal Nucleo Operativo Territo riale presso ogni Azienda Sanitaria Locale, è incaricato delle attività in materia di prevenzione e controllo della legionellosi e rappresenta, a livello aziendale, il momento d'incontro e condivisione tra il Dipartimento di Prevenzione, la Direzione Sanitaria, i reparti di ricovero, i laborato ri di analisi aziendali, oltre che di coordinamento e collaborazione con l'Agenzia Regionale per la Prevenzione e la Protezione dell'Ambiente (ARPA) provinciale. I punti deboli di ogni strategia di controllo della legionellosi sono riportabili alla mancanza di una chiara correlazione dose-effetto e di una soglia limi te ben definita , ancora oggi associate all'impossibilità di bonificare il sistema idrico in maniera definitiva. Per ridurre il rischio e il numero dei casi di malattia , il presente documento si propone di pianificare un iter omogeneo di procedure da applicare per il controllo e la prevenzione della legionellosi, ponendosi nella linea della prevenzione primaria piuttosto che in quella dell'intervento al verificarsi dei casi. - Il presente documento è rivolto a tutte le strutture sanitarie e assistenziali della Regione Puglia e fornisce indicazioni su: 1. metodi più appropriati per lo screening e la diagnosi della legionellosi; 2. modalità di campionamento per la ricerca di Legionella negli impianti idrici e aeraulici; 3. sistemi efficaci per la sorveglianza e il controllo delle reti idriche; 4. procedure e mezzi per la bonifica e la ridu zione del rischio; 5. attività di comunicaz ione e formazione degli operatori sanitari e degli addetti al controllo; 6. responsabilità medico-legali connesse al verificarsi di casi di malattia associati alle strutture coinvolte

An outbreak of pneumonia in a thermal water spa contaminated with Pseudomonas aeruginosa: An epidemiological and environmental concern

This article described an outbreak of bacterial pneumonia/bronchopneumonia in a group of visitors to a mineral water spa contaminated with Pseudomonas aeruginosa in summer 2009. The epidemiologic investigation was activated after the hospitalization for pneumonia of three people who had undergone therapy at the spa. Discharge with a diagnosis of pneumonia/bronchopneumonia in weeks 27 to 39 of 2009 of four hospitals near the spa were data-linked with the list of spa’s visitors. Environmental samples of thermal water were performed and analysed. Investigations discovered a total of 39 cases of pneumonia among the spa visitors. Checks carried out in the hospitals near the spa revealed more hospitalizations for pneumonia in summer 2009 than the average for the previous five summers. There was a significant association between pneumonia and inhalation therapy (RR=7.33; p<0.0001) and aerosol therapy (RR=8.25; p<0.0001). P. aeruginosa was discovered in the water of the inhalation equipment. The spa micro-environment offers a risk of infection from pathogenic and/or opportunistic micro-organisms and therefore in-house testing, surveillance and prevention systems should be put in place for the well-being of clients

Vaccination coverage among paediatric onco-haematological patients: an Italian cross-sectional study

Children with onco-hematological diseases are at increased risk of infection. However, this risk can in part be controlled or reduced using currently available vaccines. Despite available evidence, in patients diagnosed with a hematological or oncological disease the vaccination schedule is often inappropriately discontinued. In this study we evaluated whether the diagnosis of an oncological or hematological disease is a determinant of noncompliance with recommended vaccinations. The study was carried out between March and April 2019. The population was composed of a convenience sample of 228 children cared for in the Pediatric Oncology Department and Pediatric Hematology Department of the Policlinico Giovanni XXIII Pediatric Hospital (Bari, Italy) from 2005 to 2015. Information on the immunization status of the patients was obtained from the Apulia regional immunization database (GIAVA). A post-diagnosis adherence score was calculated. The vaccination coverage was 87.7% for the DTaP-IPV-Hep B-Hib vaccine (3 doses), 68.7% for the pneumococcal vaccine (3 doses), 75.8% for the MMR vaccine (2 doses) and 75.1% for the varicella vaccine (2 doses). The average age at vaccination was older than that recommended by the National Vaccination Plan. A diagnosis of oncological disease and an older age at enrollment were risk factors for missing vaccinations. These results showed that the overall vaccination status of pediatric onco-hematological patients is suboptimal. Improving provider communication and establishing the hospital as the primary environment for vaccine administration may lead to better vaccination compliance in this group

Indirizzi operativi per la prevenzione e il controllo della legionellosi nelle strutture turistico‐ricettive e ad uso collettivo della Regione Puglia (DGR n.920 del 6.5.2015)

Non disponibil

Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study

Background and Aims: HCV-infected patients with decompensated cirrhosis, and in particular those Child-Pugh-Turcotte (CPT) class C, are usually excluded from studies investigating the sustained virological response (SVR12) to new direct-acting antivirals (DAAs). A more refined classification of cirrhotic patients has been provided by D’Amico et al. In this system stage 1 includes patients without portal hypertension, stage 2 those with esophageal varices, stage 3 patients who bled from varices, stage 4 patients with a single episode of decompensation events, and stage 5 those with multiple decompensation events. To assess the SVR12 after therapy in patients with advanced fibrosis and cirrhosis stratified according to the D’Amico” system. To evaluate the functional outcome during the follow up after treatment. Methods:We investigated a cohort of 2612 patients, from a network of 24 Italian centers, with chronic HCV infection and advanced fibrosis (no. = 575) or cirrhosis (no. = 2037). Different DAAs schedules were administered at the physicians’ choice, in accordance with national and international guidelines. All patients have completed 3 months of follow-up post treatment. Results: At exception of bilirubin levels, numbers of patients with normal albumin and INR values increased significantly in respect to baseline. Circulating platelets and creatinine levels increased significantly in respect to baseline. A remarkable increase in the numbers of CPT class A patients became apparent, whose frequency increased from 35.9% to 80.3% (p < 0.001). During the 3 month post-treatment follow up, no decompensation events were detected in patients with advanced hepatic fibrosis; a single patient developed HCC, and one patient died for acute leukemia. Of the 1739 stage 1 and 2 cirrhotics, 33 patients (1.9%) manifested events of decompensation or a HCC, and 1 of them died for uncontrolled esophageal bleed. Among the 277 decompensated cirrhotics (stage 3 to 5), 25 subjects (9.0%) experienced single or multiple events or a HCC, 4 were transplanted being HCVRNA negative at the time of the OLT,1 died for acute hepatic failure and 1 for diabetic complications. Results are shown in the Table. Conclusions: Our findings support the safety and the efficacy of DAAs treatment even in patients with portal hypertension and decompensated liver disease (stages 3–5 or CPT class C)

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

BACKGROUND: We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. METHODS: In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with HCV genotype 1b infection) or 24 weeks (patients with HCV genotype 1a infection). Patients with HCV genotype 4 infection were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once per day for 24 weeks. All patients were given weight-based ribavirin. The primary efficacy endpoint was sustained virological response at week 12 after the end of treatment (SVR12), analysed by intention-to-treat. Univariate and multivariate logistic regression analyses were used to identify baseline characteristics associated with SVR12. Adverse events were recorded throughout the study. FINDINGS: 728 (96%) of 762 patients with cirrhosis who were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12. Logistic regression analyses identified that bilirubin concentrations of less than 2 mg/dL were associated with SVR12 (odds ratio [OR] 4·76 [95% CI 1·83-12·3]; p=0·001). 166 (23%) of 734 patients included in safety analyses had an adverse event. 25 (3%) patients discontinued treatment because of adverse events. Asthenia was the most commonly reported adverse event, occurring in 36 (5%) patients. INTERPRETATION: Our findings suggest that the safety and effectiveness of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 infection and cirrhosis at high risk of decompensation in a real-life setting are similar to those reported in clinical trials. The concordance with clinical trials provides reassurance that the reported efficacy of this treatment in clinical trials will translate to its use in routine clinical practic

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65\ua0years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100\ua0mg) and twice-daily dasabuvir (250\ua0mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12\ua0weeks after the end of treatment (SVR12). Results: Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5\ua0g/dL (OR 2.04: 95% CI 1.0\u20134.2, p < 0.05) and hypertension (OR 4.6: 95% CI 2.3\u20139.2, p < 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2\ua0mg/dL (OR 4.9: 95% CI 1.17\u201320.71, p = 0.029) as the only variable independently associated with SVR12. Conclusion: Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65